Considerations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and reality
dc.authorid | Ayşe Şeyma Büyük / 0000-0001-8934-0359 | en_US |
dc.authorid | Semra Şardaş / 0000-0001-5456-8636 | en_US |
dc.authorscopusid | Ayşe Şeyma Büyük / 57215857903 | en_US |
dc.authorscopusid | Semra Şardaş / 7003286974 | en_US |
dc.authorwosid | Ayşe Şeyma Büyük / AAM-1484-2020 | en_US |
dc.authorwosid | Semra Şardaş / DPM-9537-2022 | en_US |
dc.contributor.author | Al Taie, Anmar | |
dc.contributor.author | Büyük, Ayşe Şeyma | |
dc.contributor.author | Şardaş, Semra | |
dc.date.accessioned | 2022-11-14T11:22:21Z | |
dc.date.available | 2022-11-14T11:22:21Z | |
dc.date.issued | 2022 | en_US |
dc.department | İstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü | en_US |
dc.description.abstract | COVID-19 medicines, such as molnupiravir are beginning to emerge for public health and clinical practice. On the other hand, drugs display marked variability in their efficacy and safety. Hence, COVID-19 medicines, as with all drugs, will be subject to the age-old maxim “one size prescription does not fit all”. In this context, pharmacogenomics is the study of genome-by-drug interactions and offers insights on mechanisms of patient-to-patient and between-population variations in drug efficacy and safety. Pharmacogenomics information is crucial to tailoring the patients' prescriptions to achieve COVID-19 preventive and therapeutic interventions that take into account the host biology, patients’ genome, and variable environmental exposures that collectively influence drug efficacy and safety. This expert review critically evaluates and summarizes the pharmacogenomics and personalized medicine aspects of the emerging COVID-19 drugs, and other selected drug interventions deployed to date. Here, we aim to sort out the hope, hype, and reality and suggest that there are veritable prospects to advance COVID-19 medicines for public health benefits, provided that pharmacogenomics is considered and implemented adequately. Pharmacogenomics is an integral part of rational and evidence-based medical practice. Scientists, health care professionals, pharmacists, pharmacovigilance practitioners, and importantly, patients stand to benefit by expanding the current pandemic response toolbox by the science of pharmacogenomics, and its applications in COVID-19 medicines and clinical trials. | en_US |
dc.identifier.citation | AL-Taie, A., Büyük, A. Ş., & Sardas, S. (2022). Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulmonary Pharmacology and Therapeutics, 77 doi:10.1016/j.pupt.2022.102172 | en_US |
dc.identifier.doi | 10.1016/j.pupt.2022.102172 | en_US |
dc.identifier.scopus | 2-s2.0-85140765335 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.pupt.2022.102172 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12713/3376 | |
dc.identifier.volume | 77 | en_US |
dc.identifier.wos | WOS:000877679200002 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Büyük, Ayşe Şeyma | |
dc.institutionauthor | Şardaş, Semra | |
dc.language.iso | en | en_US |
dc.publisher | Academic Press | en_US |
dc.relation.ispartof | Pulmonary Pharmacology and Therapeutics | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Clinical Trials | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Molnupiravir | en_US |
dc.subject | Personalized Medicine | en_US |
dc.subject | Pharmacogenomics | en_US |
dc.title | Considerations into pharmacogenomics of COVID-19 pharmacotherapy: hope, hype and reality | en_US |
dc.type | Review Article | en_US |